NFATC2

Across TCGA pan-cancer cohorts, NFATC2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of NFATC2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where NFATC2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types NFATC2 is over-expressed in tumor, although a few such as PDAC and COAD show the opposite, repressed pattern.

CCRCC, PDAC, and COAD are the cancer types where NFATC2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NFATC2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.800	<.001	12	view →
PDAC	All	III,IV	−0.485	<.001	10	view →
COAD	Male	All	−0.936	<.001	9	view →
HNSC	Male	III,IV	−0.355	<.001	8	view →
LSCC	Male	III,IV	−0.379	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

NFATC2–CCRCC

Open the CCRCC breakdown →